Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 1 of 6 PageID #: 1352
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 1 of 6 PageID #: 1352
`
`
`
`
`
`EXHIBIT 57
`
`
`
`
`
`EXHIBIT 57
`
`
`
`
`
`
`

`

`11/17/2020
`
`TruSight Oncology UMI Reagents | Unique molecular identifiers for NGS
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 2 of 6 PageID #: 1353
`
`Products / Browse by Product Type / Clinical Research Products / TruSight Oncology UMI Reagents
`
`TruSight Oncology UMI Reagents
`Error correction with unique molecular identifiers (UMIs) for next-generation sequencing
`libraries.Read More...
`
`Select Product(s)
`
`TruSight Oncology UMI Reagents (16 indexes, 48 samples) 
`20024586
`Sign in to see pricing and favorite products.
`
`
`
`0
`
`Accessory Products
`What accessories do I need?
`
`TruSight® Tumor 170 Content Set 
`20010188
`Sign in to see pricing and favorite products.
`
`TruSight cfDNA UMI for HiSeq 2500 (48 Samples) 
`20023394
`Sign in to see pricing and favorite products.
`
`TruSight cfDNA UMI for HiSeq 4000 (48 Samples) 
`20023395
`Sign in to see pricing and favorite products.
`
`
`
`
`
`
`
`0
`
`0
`
`0
`
`Show 1 More 
`
`TruSight
`Oncology UMI
`Reagents
`
`Product Highlights
`
`The TruSight Oncology UMI Reagents reduce background noise in
`sequencing data, enabling detection of low-frequency variants, such as
`those found in cell-free DNA (cfDNA).
`
`Reduced Error Rates
`
`Circulating tumor DNA (ctDNA) may represent a very small fraction of
`cfDNA, near the limit of detection for next-generation sequencing (NGS).
`The TruSight Oncology UMI Reagents address this challenge with UMIs
`and error correction software, reducing error rates to < 0.007% and
`enabling detection of low-frequency variants. Lower error rates increase
`analytical specificity, resulting in higher confidence in NGS data.
`
`Integration into TruSight Oncology Workflow
`
`The TruSight Oncology UMI Reagents include UMI adapters and indexes,
`plus TruSight Oncology DNA library prep and enrichment reagents. These
`reagents can also be paired with the TruSight Tumor 170 DNA oligos.
`Integration of UMIs does not create any extra steps in the library prep
`workflow.
`
`Intuitive Software for Error Correction
`
`The UMI Error Correction App aligns reads, then uses UMIs to exclude
`false positives, reducing variant calling errors. The UMI Error Correction
`App is available in the cloud-based BaseSpace Sequence Hub or for local
`installation.
`
`https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-umi.html
`
`1/5
`
` Add To Cart
`
`

`

`11/17/2020
`
`TruSight Oncology UMI Reagents | Unique molecular identifiers for NGS
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 3 of 6 PageID #: 1354
`
`Specifications
`
`Assay Time
`
`Hands-On Time
`
`Input Quantity
`
`System Compatibility
`
`Nucleic Acid Type
`
`Cancer Type
`
`Method
`
`Technology
`
`1.5 days
`
`5 hours
`
`30 ng cell-free DNA
`
`HiSeq 2500, HiSeq 4000, NextSeq 2000, NextSeq 550, NovaSeq 6000
`
`DNA
`
`Pan-Cancer
`
`Targeted DNA Sequencing
`
`Sequencing
`
`Specialized Sample Types
`
`Cell-Free DNA, Not FFPE-Compatible
`
`Species Category
`
`Human
`
`Method-Specific Workflow Example
`
` 
`
` 
`
` 
`
`Prepare Library for:
`
`Sequence Efficiently with:
`
`Analyze Your Data with:
`
`Targeted Cancer Sequencing
`
`HiSeq 2500 System
`HiSeq 4000 System
`NovaSeq 6000 System*
`
`BaseSpace Sequence Hub
`UMI Error Correction App in BaseSpace
`Sequence Hub
`Local UMI Error Correction App
`
`Contact your local Illumina Support team to
`access the Local UMI Error Correction App.
`
` 
`
`Supporting Data and Figures
`
`Background Reduction Facilitates Accurate Variant Calling
`
`https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-umi.html
`
`2/5
`
`

`

`11/17/2020
`
`TruSight Oncology UMI Reagents | Unique molecular identifiers for NGS
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 4 of 6 PageID #: 1355
`
`To enable accurate detection of rare variants, UMIs are integrated with error correction software,
`enabling true mutations to be distinguished from background noise. The bottom panel illustrates how,
`by removing inherent errors that result in false positives, the reduced error rate allows true mutations
`(red dots) to be better distinguished from background noise (grey dots).
`
` 
`
`Reduction of Error Rates with UMIs
`
`Sequencing Run
`
`Mean Error Rate (Uncollapsed Reads)
`
`Mean Error Rate (Collapsed Reads)
`
`1
`
`2
`
`3
`
`4
`
`0.038%
`
`0.043%
`
`0.035%
`
`0.084%
`
`0.0023%
`
`0.0024%
`
`0.0024%
`
`0.0019%
`
`Library preparation was performed using the TruSight Oncology UMI Reagents paired with DNA content from the TruSight Tumor 170 DNA assay, and 31
`samples were distributed among four independent sequencing runs on the HiSeq 4000 System. Mean error rates are shown with and without collapsed
`reads using the UMI Error Correction App.
`
`Product Literature
`
`Manuals and Support Information
`
`Options for Circulating cfDNA Control Materials with NGS Analysis
`Technical Note | PDF< 1 MB
`
`Detection of low-frequency variants in cfDNA using TruSight Tumor 170
`with the TruSight UMI Toolkit
`Application Note | PDF2 MB
`
`TruSight Oncology UMI Reagents Documentation
`
`Custom Protocol Selector
`Generates customized, end-to-end instructions
`
`https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-umi.html
`
`3/5
`
`

`

`11/17/2020
`
`TruSight Oncology UMI Reagents | Unique molecular identifiers for NGS
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 5 of 6 PageID #: 1356
`
`Using TruSight Oncology UMI Reagents with TruSight Tumor 170 DNA
`Content for Detection of Low-Frequency Variants in Cell-Free DNA
`Application Note | PDF2 MB
`
`All TruSight Oncology UMI Reagents Support 
`
`TruSight Oncology UMI Reagents
`Data Sheet | PDF< 1 MB
`
`Related Products
`
`TruSight Oncology 500
`
`Assay targeting multiple variant
`types, including microsatellite
`instability (MSI) and tumor
`mutational burden (TMB).
`
`
`
`TruSight Oncology
`
`TruSight Oncology is a set of NGS
`platform reagents for the detection
`of cancer variants, using an
`enrichment-based method to
`simultaneously analyze DNA and
`RNA. Gene content is not included.
`
`BaseSpace Sequence
`Hub
`
`Data management and simplified
`bioinformatics for labs getting
`started and for rapidly scaling
`next-generation sequencing (NGS)
`operations.
`
`
`
`
`
`Related Solutions
`
`Pathology and Clinical Cancer
`Research
`
`Our clinical cancer research solutions
`deliver accurate genomic information, and
`enable labs to analyze multiple genes in a
`single test.
`
`Targeted Resequencing
`
`With targeted resequencing, a subset of
`genes or a genomic region is isolated and
`sequenced, which can conserve lab
`resources.
`
`Cancer Panels for Targeted
`Sequencing
`
`By performing targeted cancer sequencing
`with a focused gene panel, you can reduce
`costs and complete studies quickly.
`
`Learn More
`
`Learn More
`
`Learn More
`
`* Performance on the NovaSeq 6000 System was demonstrated but not extensively tested.
`
`Back to Top 
`
`Innovative technologies
`
`At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that
`were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet
`the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and
`providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling
`groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
`For Research Use Only. Not for use in diagnostic procedures.
`
`© 2020 Illumina, Inc. All rights reserved.
`
`
`
`
`
`
`
`
`
`https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-umi.html
`
`4/5
`
`

`

`11/17/2020
`
`TruSight Oncology UMI Reagents | Unique molecular identifiers for NGS
`Case 1:20-cv-01644-RGA Document 1-57 Filed 12/03/20 Page 6 of 6 PageID #: 1357
`
`All trademarks are the property of Illumina, Inc. or their respective owners.
`For specific trademark information, see www.illumina.com/company/legal.html.
`
`Privacy Policy
`
`https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-umi.html
`
`5/5
`
`